We hypothesize that chronic intraprostatic inflammation contributes to the development of prostate cancer. Chronic inflammation may serve as an initiator and/or promoter of prostate carcinogenesis as it does in infection-associated liver and stomach cancer and in colon cancer in inflammatory bowel disease. Indeed, regions of atrophy showing hyperproliferation and inflammation, called proliferative inflammatory atrophy (PIA) lesions, are common in the prostate. These lesions may be regenerative and may be the result of response to infection or cell trauma due to oxidant damage or hypoxia. To address this hypothesis, we propose to evaluate the association of tissue, circulating, and genetic markers of inflammation, its sources, or sequelae with prostate cancer. Prostate cancer cases and age frequency-matched controls who were negative on an end-of-study biopsy will be selected from among participants in the Prostate Cancer Prevention Trial (PCPT). In biopsy sections from 400 cases and 400 controls, we will determine the prevalence, extent, and biological characteristics of inflammation and atrophy using immunohistochemistry or FISH and image analysis. We will detect antibodies against 5 infectious agents (e.g., Chlamydia trachomatous, Trichomonas vaginalis) by ELISA in serum from 600 cases and 600 controls. We will genotype 1800 cases and 1800 controls for germline polymorphisms in 12 genes involved in the innate and adaptive immune response to infection and tissue damage (e.g., TLR-4, IFNy,IL-10) using MALDI-TOF. We will use logistic regression to estimate the odds ratios of prostate cancer and high-grade disease. Jointly with the other Projects, we will test whether the associations vary by exposure to factors that may alter adverse effects of inflammation, including the PCPT study drug finasteride, levels of serum antioxidants, sex steroid hormones, and growth factors. Given that inflammation is a clear target for intervention, we anticipate that the proposed work will have important implications for prostate cancer prevention. The revised Project addresses all reviewer concerns, including those for new preliminary data on the association of inflammation with prostate cancer in the PCPT and additional immunology expertise.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA108964-05
Application #
7810537
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
5
Fiscal Year
2009
Total Cost
$225,668
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Tang, Li; Platek, Mary E; Yao, Song et al. (2018) Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis 39:125-133
Winchester, Danyelle A; Till, Cathee; Goodman, Phyllis J et al. (2017) Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. Prostate 77:908-919
Miles, Fayth L; Goodman, Phyllis J; Tangen, Catherine et al. (2017) Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients 9:
Chen, Haitao; Liu, Xu; Brendler, Charles B et al. (2016) Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. Prostate 76:1120-9
Murtola, Teemu J; Gurel, Bora; Umbehr, Martin et al. (2016) Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev 25:463-9
Price, Douglas K; Chau, Cindy H; Till, Cathee et al. (2016) Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial. Cancer 122:2332-40
(2016) Correction: Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 9:116-7
Patel, Darshan P; Schenk, Jeannette M; Darke, Amy et al. (2016) Non-steroidal anti-inflammatory drug (NSAID) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial. BJU Int 117:500-6
Travis, Ruth C; Appleby, Paul N; Martin, Richard M et al. (2016) A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Res 76:2288-2300
Winchester, Danyelle A; Gurel, Bora; Till, Cathee et al. (2016) Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. Prostate 76:565-74

Showing the most recent 10 out of 71 publications